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Abstract 
 
Mental and brain disorders represent the greatest health burden to Europe—not only for 
directly affected individuals, but also for their caregivers and the wider society. They incur 
substantial economic costs through direct (and indirect) health-care and welfare spending, and 
via productivity losses, all of which substantially affect European development. Funding for 
research to mitigate these effects lags far behind the cost of mental and brain disorders to 
society. Here, we describe a comprehensive, coordinated mental health research agenda for 
Europe and worldwide. This agenda was based on systematic reviews of published work and 
consensus decision making by multidisciplinary scientific experts and affected stakeholders 
(more than 1000 in total): individuals with mental health problems and their families, health-
care workers, policy makers, and funders. We generated six priorities that will, over the next 5–
10 years, help to close the biggest gaps in mental health research in Europe, and in turn 
overcome the substantial challenges caused by mental disorders. 
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Introduction 
Costs and burdens of mental and brain disorders 
A strong need exists for parity in service provision and research between mental and physical 
disorders. Mental and brain disorders represent the single largest contributor to disease burden 
in Europe.1 More than one in three Europeans experience mental health problems each year,1 
and even more will be affected indirectly, including family members, health systems, and the 
wider society. The increasing age of the European population means that the long-term mental 
health burden is greater now than it has ever been.2 As of 2010, the estimated yearly cost of 
mental disorders in Europe is €461 billion,3 excluding any costs of dementia and other 
neurological disorders. Beyond direct costs to health services, this figure is mainly due to 
indirect costs to social welfare, employment, wellbeing, and economic output. These costs are 
not decreasing. For example, disability benefits in the UK and Germany have been fairly stable, 
but the proportion accounted for by mental health disorders continues to rise.4,5 
People with mental health problems experience earlier death6 by as much as 20 years.7 Such a 
reduction in lifespan might be due to an increased risk for physical health problems such as 
cardiovascular disease,8 or because individuals with mental health problems do not seek early 
treatment for their mental or physical health.9 Alongside evidence of early mortality is the 
shocking statistic that, in Europe, an estimated 1·5 million people attempt suicide each year, and 
100000 complete it.10 In England and Wales, suicide is the top cause of death for women and 
men aged 20–34 years and for men aged 35–49 years,11 and it is a leading cause of death in 
men aged 19–30 years in Europe and worldwide.12 
Most mental health problems are chronic and begin early in life (50% before the age of 15 years 
and 75% before the age of 18 years),13 and this realisation is fuelling calls for interventions in 
childhood to avert the development of long-term problems. However, the best possible 
interventions or which groups of children are most at risk of developing long-term problems 
are unknown. 
 
Mental health problems increase other health costs 
The costs of care increase strikingly if individuals with physical disorders have a comorbid 
mental health problem, so cost estimates are conservative because they do not take this 
comorbidity into account. For people with rheumatoid arthritis, the costs of care nearly double 
if they have depression,14 and for asthma the increase is 140%.12 People with depression also 
face a higher risk of developing heart disease than individuals without depression; following a 
heart attack, each additional depressive symptom that develops increases the risk of another 
heart attack by 15%.15 Individuals with diabetes who develop a foot ulcer and also have 
depression have a high early-mortality rate (30% within 18 months of developing foot ulcer, 
three times higher than in those without depression).16 Therefore, successful treatment of 
mental health problems has potential advantages to individuals and to health services by 
reducing costs, morbidity, and mortality associated with a wide range of physical disorders, in 
addition to reducing the direct costs of mental disorders. 
As well as mental disorder being increasingly associated with high costs, evidence also exists 
that research into mental health has demonstrable positive effects. For example, the RAND 
Mental Health Retrosight project shows that, over 20 years, developments in basic and clinical 
research in schizophrenia (eg, locating γ-aminobutyric-acid-A receptors in the brain, early- 
intervention research, and trials of supported employ- ment) have a beneficial effect on patient 
care and positive wider social and economic effects.17 
 
Investing in mental health research 
A good return on investment 
Funding mental health research generates a good return on investment. For every pound 
sterling spent on mental health research in the UK, the yearly recurring return is estimated to 
be £0·37, which is similar to the return for research on cardiovascular disorders18 and 
cancer.19 Giant steps have been made in research into the mechanisms of and treatments for 
cardiovascular disease and cancer, and marked improvements have been reported 
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subsequently to health services and lifestyle advice offered for patients with these disorders. 
These improvements resulted in the 20% decrease in cancer mortality seen over 1993–2013.20 
For mental health, a boost in research investment could have similar large effects within a fairly 
short time, reducing not only the burdens on individuals and families but also the costs of care 
and support in the long term.  
 
Uneven research funding distribution  
Public funding for mental health research available at the European level is disproportionately 
low compared with the effect of mental disorders on population health. Mental disorders 
account for between 11%21 and 27%1 of the disability burden in Europe22,23 but receive less 
than 5% of the overall health research budget of the European Commission’s Seventh 
Framework Programme (FP7).24,25  
For national funding, the figures are no more encouraging: the percentages of funding for 
mental health research compared with the overall health research funding are 2% in France and 
7% in the UK.26 In England, mental disorders cost between £70 billion27 and £105 billion per 
year,28,29 but only £115 million— which could be as low as a thousandth of the yearly cost of 
mental disorders—is invested in mental health research in the UK.30 For comparison, cancer 
research received more than 4·5 times as much funding (£521 million) as mental health 
research in 2011,31 although cancer accounts for only 15·9% of the UK’s total disease burden, 
compared with 22·8% for mental disorders.32 In France, mental disorders cost €108 billion per 
year, but only €25 million is allocated to psychiatry research.29  
Although physical health research can attract substantial third-sector funding, the case is not 
the same for mental health research. An analysis30 showed that for every pound sterling that 
the UK Government spent on research in cancer, circulatory problems, and mental health, the 
research funding from charities was £2·75, £1·25, and £0·0003, respectively. We suspect that 
this pattern is the same across Europe. With such a low charitable investment, years of 
campaign building will be needed to redress the gap in funding. In the meantime, substantial 
increases in government spending would help to bring funding for mental health research in 
line with the costs of mental health problems to society.  
Preventive research could be especially useful to offset the costs of mental disorders,33 but this 
area receives especially low levels of funding at present. For example, in the UK, only £4·5 
million (0·17–0·28% of the total yearly spend on health research) is spent on preventive mental 
health research per year.30,34  
 
Poised for action  
Europe is now well placed to respond to the challenges resulting from mental health problems.  
 
Scientific advantage  
In the past 10 years, ground breaking advances have been made in biological and brain sciences 
(eg, biomarkers from -omics research, developments in brain mapping such as the connectome, 
fast genome- wide association studies, high-throughput and next- generation DNA sequencing), 
eHealth and technology (eg, web-based treatments, applications to monitor symptoms on smart 
phones and tablets), psychological therapies (use and implementation of cognitive behavioural 
therapy), and research infrastructure (open-access publication, European research 
networks).35 These developments should be used to generate more evidence along the whole 
translational pipeline from biological mechanisms to clinical implementation and preventive 
interventions, allowing the delivery and promotion of improved treatments.  
 
European research advantage  
Europe’s diverse health systems with near-universal coverage offer the ability to collect so-
called big data, with access to health registers and oversight of paths to care.36 These features 
collectively produce rich and representative datasets that are not available elsewhere. An added 
advantage is that Europe is home to many initiatives for inclusion of individuals with mental 
health problems in the design and management of research.37,38 Service user involvement 
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improves research feasibility,39 treatment acceptability, and ease of transfer to the wider 
health system, and will only become more important over time.  
As a result, European research is singularly well placed to address many challenges in mental 
health in the next 5–10 years. This fact, in addition to the need for research into the prevention 
of mental disorders, has been recognised by the European Parliament and European 
Commission.40,41 All that is required is an agenda for action, which is the focus of this Personal 
View.  
 
A comprehensive and inclusive priority development method   
ROAMER (Roadmap for Mental Health Research in Europe)42,43 was set up to develop the 
agenda for mental health research with immediate and long-term priorities (panel 1). It covers 
the mental disorders named in the 2010 Global Burden of Disease study21 but not 
neurodegenerative disorders (eg, Alzheimer’s disease and other types of dementia).21 ROAMER 
was given ethical approval by the European Commission’s FP7 ethics review process.  
The ROAMER programme consisted of multi- disciplinary work packages and advisory boards 
that covered the broad range of approaches to mental health research (figure).43 The areas 
covered by each of the work packages were decided by consensus in meetings of the ROAMER 
steering committee of scientific experts and advisory boards. Scientific work packages (ie, work 
packages 4–8 and the clinical research task force) were complemented by the stakeholder and 
scientific advisory boards,44 who provided input and direction across the entire course of the 
ROAMER project to map the types of mental health research (eg, randomised controlled trials 
and epidemiology), capacity, funding, and infrastructure geographically across the EU-27 
countries. Work package 2 mapped the numbers of studies conducted in five different areas of 
research within mental health (epidemiology, clinical randomised controlled trials, biological: 
genetics and imaging, psychological therapy, and mental health stigma) in each of these 
countries. All groups were advised to take into account the European (not just national) 
perspectives in research, funding, and societal needs, demographic changes occurring in 
Europe,2,41 and gender aspects of mental disorders.  
The ROAMER project consisted of two phases. The first phase provided a mapping and gapping 
report based on systematic reviews of published work and was done by the scientific work 
packages and work package 2.45–48 70761 articles were retrieved, of which 28188 were used 
in the final mapping, highlighting the volume of different kinds of mental health research across 
Europe. For example, the UK is strong in clinical randomised controlled trials, Iceland leads 
genetic studies, and Serbia is strong in stigma research. The systematic mappings were used 
together with expert workshops, consensus meetings, modified Delphi methods, and surveys to 
establish, for each work package, the major research advances that had been achieved 
worldwide in the past 10 years and the further developments that were needed to overcome 
extant gaps.  
In the second phase, research priorities and advances needed were established from each work 
package and integrated across the programme: scientific reports43,44,48–52 provide details on 
each work package. All research priorities were justified in consensus meetings on the basis of 
their likely efficacy and effectiveness, European effects and economic benefits, deliverability 
and answerability in Europe, and relevance to European strengths. These justifications ensured 
that all output of the ROAMER project took into account social, political, and economic contexts 
in Europe and existing European infrastructure, while strongly representing priorities of 
stakeholders.  
The 151 priorities generated by the individual work packages were integrated into a single list 
of 20 priorities. Feedback via a survey was gathered on these 20 priorities from 486 scientific 
experts and 245 stakeholder organisations across Europe (figure). Survey participants rated 
each priority on a ten-point scale for their relative relevance (ie, the likelihood that the advance 
will result in an effective intervention to improve mental health) and feasibility (ie, the 
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likelihood that the advance can be achieved) in Europe. Strong agreement was reached about 
the most highly rated priorities between different stakeholders, albeit in slightly different 
orders.  
The process of prioritisation was based on input from more than 1000 expert researchers and 
stakeholder organisations. For comparison, the prioritisation exercise used to determine the 
Grand Challenges in Global Mental Health involved only 422 individuals53 and, unlike ROAMER, 
did not include service users. This breadth of input, together with the comprehensive and 
systematic mapping process, makes ROAMER the most inclusive and comprehensive 
prioritisation process in mental health research so far.  
This consensus-based decision-making process has generated six overarching research 
priorities that are targeted, actionable, and built on excellent European science (panel 2). 
Moreover, research dedicated to these priority areas would result in a substantial reduction of 
the costs and burdens associated with mental health in Europe within the next 5–10 years.  
 
Where Next? 
Many issues highlighted by the ROAMER project will be familiar to individuals who are 
concerned with mental health for either personal or professional reasons. Other governments 
and scientific com- munities—including WHO53 and the US National Institute for Mental 
Health54—have developed priorities for mental health, some of which overlap with the 
ROAMER priorities—eg, the development of new interventions, and lifespan and aetiological 
research. However, the content of the ROAMER priorities differs in meaningful ways, not least in 
the prominence of priorities that relate to stigma reduction, those that involve stakeholders in 
research, and those that take into account social, cultural, and economic contexts, and 
comorbidity and eHealth applications. We expect that these additions are representative of the 
input from service users and other stakeholders in ROAMER, and no doubt the technological 
advances and scientific understanding gained over the past 10 years.  
Two main differences exist in the present landscape of mental health compared with that of the 
past, which make the ROAMER research priorities both particularly urgent and ready for 
translation, and which might promote their imminent uptake by researchers and decision 
makers.  
The first issue is that the costs of mental disorder have increased and are set to continue rising, 
such that inaction on evidence-based mental health policy is no longer an option. ROAMER’s 
priorities are similar in part to the priorities of the past 10 years; these priorities could and 
should have been answered decades ago, but poor investment and the absence of a coordinated 
research strategy have hampered the evidence-gathering process. A boost to investment in 
mental health research can help to resolve research questions, inform policy, improve mental 
health care and, in the long term, reduce their burden to individuals, their families, and the 
society. In particular, an increase in government funding is needed at both the national level and 
the European level for mental health research to address the present shortfall compared with 
the cost that mental disorders pose to European society.  
The second issue is that infrastructure now exists in Europe to address issues in mental health 
in a way that was not previously possible. Open-access publication, open-data policies, and 
European research networks mean that, for the first time, the opportunity to develop shared 
databases and international networks has become real. Genome-wide association studies and 
next-generation sequencing (eg, whole-exome or whole-genome sequencing) are now quick and 
inexpensive enough that systematic identification of biomarkers to drive treatment 
development is a real possibility.35  
Research questions identified by ROAMER are closely aligned with the Horizon 2020 priorities 
in personalised care—ie, mental health care that takes into account individual variation in and 
between service users in terms of care, diagnosis, and service provision. ROAMER’s priorities 
for preventive measures have also been advocated by the European Parliament,40 the 
European Commission (notably, in the identification of the particular importance of “Effective 
7 
 
health promotion, disease prevention, preparedness and screening” in Horizon 2020),41 and in 
many European countries. Scientists now have a coordinated and highly applicable research 
strategy from the ROAMER project, and they need to be encouraged to engage with policy 
makers and funders to implement this strategy. By making timely use of the resources that 
Europe has at its disposal, European researchers will be able to address some of the biggest 
societal challenges that mental disorders represent at present.  
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Panel 1: The ROAMER project  
Before the ROAMER (Roadmap for Mental Health Research in Europe) project, agenda-setting 
processes for mental health research (eg, the Grand Challenges in Global Mental Health or the 
WHO’s Mental Health Gap Action Programme Intervention Guide) used expert panels of 
scientists and clinicians to establish research priorities, but they did not include input from 
wider stakeholders. Therefore, these processes have been restricted in scope and implications 
for future effects because of the absence of interdisciplinarity. The ROAMER project aims to 
overcome these restrictions.  
ROAMER work packages systematically mapped and reviewed published work to describe 
mental health research in Europe. PubMed and PsycINFO databases were searched for scientific 
reports published between Jan 1, 2007, and Dec 31, 2011, in different knowledge areas 
comprising mental health, mental and behavioural disorders, and wellbeing conducted in any 
European country. The areas were defined on the basis of the work package structure of the 
project—namely, research into biomedicine; psychological treatments; social and economic 
issues; public health; wellbeing; geographical, multidisciplinary, and lifespan viewpoints; and 
research funding, infrastructures, and capacity building (figure). Studies were selected either if 
they were set in or if they had a corresponding author based in one of the (as then) EU-27 
countries.  
ROAMER is the largest agenda-setting exercise in mental health research, involving more than 
1000 individuals and associations. Unlike previous work, our project was not restricted to 
scientists but included a wide range of stakeholders, such as individuals with mental health 
problems and their families, clinicians and other health-care workers, policy makers, and 
industry. The project’s focus on interdisciplinarity (figure) also ensured that findings assessed 
the wide remit of mental health research and are therefore both comprehensive and of broad 
interest.  
Our findings highlight the need to increase mental research funding and to coordinate research 
policies, and they point to a series of robust and feasible research actions that can be taken at 
the European level. These actions will be able to overcome identified gaps in research 
knowledge within the next 5–10 years, and in doing so address the increasing societal 
challenges associated with the burden caused by mental disorders.  
 
Panel 2: The six research priorities for policy action in mental health and wellbeing 
research*  
Research into mental disorder prevention, mental health promotion, and interventions 
in children, adolescents, and young adults  
• Perform and sustain long-term prospective cohort studies  on the determinants of 
mental health and wellbeing to   study risk and protective factors of mental disorders    
• Develop pharmacological and psychological treatments for   children and adolescents    
• Improve mental health promotion and social exclusion  prevention in schools    
• Investigate whether prevention of depression in  pregnant women protects against 
later mental disorder or dysfunction (eg, depression) in children, and the  cost benefits 
of doing so    
• Perform longitudinal observational studies to analyse the effects of intense use of new 
forms of media (eg, the internet, gaming, and social media) in early age and adolescence 
on later emotional and cognitive competence    
 
Focus on the development and causal mechanisms of mental health symptoms, 
syndromes, and wellbeing across the lifespan (including older populations)    
• Identify factors underlying comorbidity and multimorbidity,   extending 
aetiopathogenic research on single disorders to   typical comorbid constellations    
• Define the functional characteristics of neurobehavioural  mechanisms across the 
lifespan    
• Identify social and biological factors that underlie risk or   resilience factors for mental 
disorders across the lifespan  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• Study the effects of financial crises on mental health    
• Understand how vulnerabilities and stress affect critical  developmental trajectories for 
poor health and specific mental disorders across the lifespan (but particularly in 
childhood and adolescence)    
• Study what brain abnormalities predict future mental disorder using longitudinal 
structural and functional neuroimaging    
 
Develop and maintain international and interdisciplinary research networks and shared 
databases    
• Increase the number, quality, and efficiency of international   and interdisciplinary 
networks    
• Develop multidisciplinary training programmes for mental  health research across 
different countries    
• Implement standardised European research outcomes,  databases, and terminology for 
mental health and  wellbeing research    
• Establish access to European mental health databases   across different studies with 
standardised mental health outcomes    
 
Develop and implement better interventions using new scientific and technological 
advances    
•  Strengthen research into new approaches and technology for mental health promotion, 
disorder prevention, mental health care, and social service delivery  
•  Test the value of internet-based treatments as automated versions of standard 
psychological treatments in specialised mental health care, in so-called indicated 
prevention, and particularly for use in primary care settings  
•  Test real-time psychometric feedback over the course of treatment (supported by 
modern software) to adapt dosage and intensity of treatment to service users’ complexity 
and problem profile to promote better outcomes  
•  Examine acceptability and adherence of eHealth treatments (eg, for depression), the 
clinical improvement at 1-year follow-up, and the cost-effectiveness of the intervention in 
comparison with conventional psychological therapies  
•  Understand why some individuals do not respond to treatment by identification of 
relevant, and potentially developmental-phase-specific, mediating and moderating 
variables of evidence-based psychotherapies for youths with mental disorders  
 
Reduce stigma and empower service users and carers in decisions about mental health 
research   
•  Study how carers and family members of people with mental health problems might 
perceive and experience stigma by association   
•  Identify the best methods to measure and value unpaid care  
•  Pinpoint the most cost-effective elements of anti-stigma interventions   
•  Study the role of stigma in the wider context of inequalities (eg, health inequalities) and 
implement interventions to assess and change the role of stigma in access to public services  
•  Establish better national or local interventions to address stigma, social exclusion, and 
discrimination by a careful definition of the essential questions (ie, who should be targeted; 
how, by whom, and when should targeting be done) and to determine how and by whom they 
can be assessed  
 
Establish health-systems and social-systems research that addresses quality of care and 
takes into account sociocultural and socioeconomic contexts and approaches  
•  Investigate the effect of differences in the organisation and delivery of national health-
care systems on wellbeing of individuals with mental disorders and their carers   
•  Study, at the health-systems level, the cost-effectiveness of different ways to finance, 
regulate, organise, and provide services that promote and protect mental health  
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•  Design and investigate methods to assess outcomes from mental health services that can 
be easily and reliably implemented  
*The order of priorities does not represent any ranking.  
 
 
Figure: Overview of ROAMER ROAMER=Roadmap for Mental Health Research in Europe. 
WP=work package.  
 
 Function  Members  
Scientific work packages  
WP4  Biomedical research  
Scientific experts from a range of backgrounds 
(eg, neuroscience, psychology, psychiatry, 
economics, sociology, medicine, social policy). 
Some experts held dual roles (eg, as clinician 
researchers, service users)  
WP5  
Research into psychological 
processes and treatments  
WP6  
Research into social and 
economic issues  
WP7  Public health research  
WP8  Wellbeing research  
Clinical 
research task 
force  
Clinical research  
Other work packages to map research or generate priorities  
WP2  
Geographical, 
multidisciplinary, and 
lifespan research  Scientific experts from a range of backgrounds. 
Some experts held dual roles (eg, as clinician 
researchers, service users)  
WP3  
Research into funding, 
infrastructures, and 
capacity building of mental 
health research  
Other work packages  
WP1  
Coordination and project 
management  
Scientific experts  WP9  
Coordination of stakeholder 
involvement  
WP10  Dissemination of results  
WP11  Report writing  
Other work packages  
Scientific 
advisory 
board  
External specific and 
methodological advice and 
guidance  
Scientific experts covering all areas within 
mental health who are not involved in ROAMER 
work packages  
Stakeholder 
advisory 
board  
Direction and input from 
non-academic stakeholders, 
coordinated by WP9  
Representatives of European associations of 
service users, families and carer groups; 
psychiatrists; other health or mental health 
professionals; social workers; individuals in the 
public health sector; policy makers; and funders  
 
 
 
 
 
